Therapeutic effect of paclitaxel liposome combined with cisplatin for III～IV degrees of cervical cancer

Objective To evaluate therapeutic effect and safety of paclitaxel liposome combined with cisplatin for patients with Ⅲ~Ⅳ degrees of cervical cancer in concurrent chemoradiotherapy in absence of pretreatment.Methods 32 patients with cervical cancer were randomly divided into research group(n=15) and control group(n=17).The patients in the research group were treated with paclitaxel liposome combined with cisplatin(TP regimen: 135mg/m2 of paclitaxel liposome at the first day given intravenously lasting for at lest 3 hours,55mg/m2 of cisplatin fractionally given in the first two days,there after the patients were not given any chemotherapeutic agents.3 weeks was as a cycle and the patients received 3 treatment cycles totally).Those patients in the control group were treated with paclitaxel combined with cisplatin(TP regimen: same usage as in the research group).Treatment was repeated every three weeks,at the end of the treatment cycle,the therapeutic effects in the two groups were evaluated.Results The total effective rates were 66.7% in the research group and 64.7% in the control group and thaws no significant difference between the two groups(P0.05).The side effects included myelosuppression(46.7% vs 82.4%),gastrointestinal reactions(40.0% vs 76.5%) and there were significant differences between the two groups in side effects(χ2=4.50,4.39,respectively,both P0.05).Conclusion In TP regimen with paclitaxel liposome,pretreatment with corticoid was not needed,which exempts side effects of the hormone.TP regimen with paclitaxel liposome had same therapeutic effect to TP regimen with paclitaxel and less side effects.